Loading...
Loading...
India's pazopanib imports from MALAYSIA total $993 across 6 shipments from 2 foreign suppliers. NOVUGEN PHARMA (MALAYSIA) SDN. BHD,. leads with $727 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include LAMBDA THERAPEUTIC RESEARCH LIMITED. This corridor reflects India's pharmaceutical import demand for pazopanib โ a concentrated sourcing relationship with select suppliers from MALAYSIA.

NOVUGEN PHARMA (MALAYSIA) SDN. BHD,. is the leading Pazopanib supplier from MALAYSIA to India, with import value of $727 across 4 shipments. The top 5 suppliers โ NOVUGEN PHARMA (MALAYSIA) SDN. BHD,., NOVUGEN ONCOLOGY SDN. BHD. โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | NOVUGEN PHARMA (MALAYSIA) SDN. BHD,. | $727 | 4 | 73.2% |
| 2 |
| NOVUGEN ONCOLOGY SDN. BHD. |
| $266 |
| 2 |
| 26.8% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | LAMBDA THERAPEUTIC RESEARCH LIMITED | $993 | 6 | 100.0% |
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Pazopanib suppliers from MALAYSIA to India include NOVUGEN PHARMA (MALAYSIA) SDN. BHD,., NOVUGEN ONCOLOGY SDN. BHD.. The leading supplier is NOVUGEN PHARMA (MALAYSIA) SDN. BHD,. with import value of $727 USD across 4 shipments. India imported Pazopanib worth $993 USD from MALAYSIA in total across 6 shipments.
India imported Pazopanib worth $993 USD from MALAYSIA across 6 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Pazopanib sourced from MALAYSIA include LAMBDA THERAPEUTIC RESEARCH LIMITED. The largest buyer is LAMBDA THERAPEUTIC RESEARCH LIMITED with $993 in imports across 6 shipments.
The total value of Pazopanib imports from MALAYSIA to India is $993 USD, across 6 shipments and 2 foreign suppliers. Data source: Indian Customs (DGFT).
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
6 Verified Shipments
2 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists